Clinical Trial Update: A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study of HGS1029 in relapsed or refractory lymphoid malignancies was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoid Malignancies

Drugs mentioned

• HGS1029

Snippet

Sponsor: Human Genome Sciences Inc. | Conditions: Lymphoid Malignancies | Phase 1 | Status: TERMINATED